Get access

Early treatment benefits of ropinirole prolonged release in Parkinson's disease patients with motor fluctuations


  • Potential conflict of interest: BH has received research support, honoraria, and consulting fees from GlaxoSmithKline. Nancy Earl is a former employee and shareholder at GlaxoSmithKline. Robert Hauser has received funds for speaking and consulting from GlaxoSmithKline. Duke University has received research and unrestricted educational grant funding attributed to Dr. Stacy from Allergan, Ceregene, Eisai, Merck, NIH, Novartis, Parkinson Study Group, Solvay, and Schering-Plough.


We performed a retrospective analysis of the Efficacy And Safety Evaluation in Parkinson's Disease (EASE-PD) Adjunct Study, assessing the minimum time to symptom improvement after initiation of ropinirole prolonged release (2–24 mg/day) versus placebo in patients with moderate-to-advanced PD not optimally controlled with levodopa. Ropinirole prolonged release was superior to placebo at Week 2 for change from baseline in “off” time (adjusted mean treatment difference [AMTD] – 0.7 hours; 95% confidence interval [CI], –1.1, –0.2; P = 0.0029), and “on” time without troublesome dyskinesia (0.4 hours; 95%CI, 0.01, 0.88; P = 0.0444). At Week 4, improvements were seen in change from baseline in Unified Parkinson's Disease Rating Scale total motor score (AMTD, –3.1; 95%CI, –4.4, –1.8; P < 0.0001), activities of daily living score (AMTD, –1.1; 95%CI, –1.7, –0.5; P = 0.0004), and the cardinal symptoms of PD compared with placebo. These analyses indicate that once-daily, adjunctive ropinirole prolonged release can offer PD symptom control 2 weeks after treatment initiation. © 2010 Movement Disorder Society

Get access to the full text of this article